Common use of Publications and Presentations Clause in Contracts

Publications and Presentations. (a) Corvus may publish or present the final results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with this Section 8.2); provided that Corvus gives Genentech an 2.1. Each Party shall provide to the JSC the opportunity to review and provide comments in accordance with subsection (b). (b) In any of the event that either Party (for purposes of this Section, the “Publishing submitting Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions or presentations (including information to be presented verbally) which relate to the Research Program, the Development of oral presentations) a Candidate or the Commercialization of a Product at least [*****] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [***]**] day period, in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed by the Reviewing Party; provided, however, at the request of the Reviewing PartyJSC, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b). (b) In the event that either activities hereunder. Each Party (for purposes of this Sectionagrees that, the “Publishing Party”) wishes to publish or present any Study Data or Sample Dataexcept as required by Applicable Laws, the Publishing it shall [********]. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including information to be presented verbally) that relate to the Research Program [********] at least [********] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Further, AstraZeneca shall [********]. Once an abstract, manuscript or presentation has been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********], in the case of abstracts) prior same abstract, manuscript or presentation does not have to be provided again to the date of other Party for review for a later submission for publication or publication. Each Party also shall have the date of presentation, whichever is earlier, of right to require that any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but its Confidential Information that is disclosed in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific customary standards. All such abstracts, manuscripts and academic standards presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and customs(b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. (a) Corvus Jazz and its Affiliates may publish or present present, or permit to be published or presented, the final design (including clinical design, but excluding any Codiak Platform Know-How) or results of the Study Development, Manufacture, Commercialization, or other Exploitation of the Collaboration Targets, Licensed Compounds, or Licensed Products (in accordance with this Section 8.2the “Covered Results”); provided that Corvus gives Genentech an opportunity . Codiak agrees that, except as required by Applicable Laws, it and its Affiliates shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing Party”) wishes Covered Results without the prior review by and approval of Jazz, which approval shall not be unreasonably withheld, conditioned or delayed; provided, that it shall be deemed reasonable for Jazz to withhold its consent to any request by Codiak to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Jazz or its Affiliates. Each Party shall submit provide to the other Party the opportunity to review each of the submitting Party’s proposed (a) abstracts and manuscripts for purposes of this Section, the “Reviewing Party”) all materials related scientific journals or conferences that relate to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of intended submission for publication or the date of presentationpublication, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond (b) presentations at scientific conferences (including information to be presented verbally) that relate to the Publishing Party as soon as reasonably possible, but in any case within Covered Results at least [***] (or [***], in the case of abstracts) of receipt thereofprior to its intended presentation. The Publishing Upon written request from a Party will be permitted to publish or present given within such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Partyapplicable review period, the Publishing other Party shall (i) delete from not submit such abstract or manuscript for publication or make such presentation until appropriate patent applications are filed to protect any unpatented Know-How disclosed in such publication or presentation that such Party reasonably believes may be patentable and (ii) remove any Confidential Information of such Party that is disclosed in any such proposed publication or presentation Confidential Information of prior to such publication or presentation. Once such abstracts, manuscripts or presentations (or the Reviewing Party (including Sample Data)information contained therein) have been reviewed and, provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed applicable, modified for publication or presentation contains patentable subject matter owned solely pursuant to this Section 9.4, the same abstracts, manuscripts or jointly presentations (and the information contained therein) do not have to be provided again by one Party to the Reviewing Party, delay such proposed other Party for review for a later submission for publication. In any permitted publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations presentation by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may Syndax shall publish or present the final results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity , whether such results are positive or negative in any respect, such as with respect to review and provide comments the Combination or either Compound. Authorship of publications or presentations of any Study Data or Sample Data shall be determined in accordance with subsection (b). (b) appropriate scientific and academic standards and customs. In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [*** (or ***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [*** (or ***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample DataData owned solely or jointly by the Reviewing Party), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing results of the Research Program or any Development Program without the prior review by and approval of the other Party”) wishes to publish or present any Study Data or Sample Data, the Publishing . Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Research Program or any Development Program at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***], in ] Portions of this Exhibit were omitted and have been filed separately with the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request Secretary of the Reviewing Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party (i) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards meetings and customs(ii) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing results of the Research Program without the prior review by and approval of the other Party”) wishes to publish or present any Study Data or Sample Data, the Publishing . Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Research Program at least [***] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***]day period, in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (days from the date of such written request to seek appropriate patent protection for any material in such publication or [***]presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing subject matter disclosed in such abstracts, manuscripts Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company's application requesting confidential treatment under Rule 406 of the Securities Act. or presentations does not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Subject to the foregoing obligations of this Section 6.3, TAKEDA may use the results of the Research Program for the purpose and to the extent necessary to develop and commercialise Products in accordance with this Agreement. Notwithstanding the foregoing, TAKEDA shall exclusively control all scientific publications and academic standards presentations that contain any data relating to an Optimized Lead Compound or Product. ARCHEMIX agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, any data arising out of the Development Program relating to an Optimized Lead Compound or Product without the prior review and customsexpress written approval of TAKEDA which may be withheld at TAKEDA’s sole discretion.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing results of the Research Program or any Development Program without the prior review by and approval of the other Party”) wishes to publish or present any Study Data or Sample Data, the Publishing . Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Research Program or any Development Program at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***]] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party (i) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards meetings and customs(ii) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Research Program to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Novartis to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the publication or Sample Data, the Publishing dissemination of such Covered Results by Novartis. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***]] days from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish or present The Parties acknowledge that scientific lead-time is a key element of the final value of the Research Activities under the Research Program and further agree that scientific publications must be strictly monitored to prevent any adverse effect from premature publication of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an Research Activities hereunder. Accordingly, neither Party shall publish, present or otherwise disclose any material related to the results of the Research Program without the prior review by the other Party. The publishing Party shall provide the other Party the opportunity to review and provide comments in accordance with subsection each of the publishing Party’s proposed abstracts, manuscripts or presentations (b). (bincluding information to be presented verbally) In that contain the event that either Party (for purposes of this Section, the “Publishing non-publishing Party”) wishes to publish ’s Confidential Information or present disclose any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials unpatented Information related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions results of oral presentations) the Research Program at least [***] days (or [***], in the case of abstracts) prior to its intended presentation or submission for publication, and the date of submission publishing Party agrees, upon written request from the non-publishing Party given within such thirty (30)-day period, not to submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever non-publishing Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] days (or [***], such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any unpatented Information disclosed in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation that it reasonably believes may be patentable. Notwithstanding the foregoing, in no event shall a Party have the right, in reliance on this Section 7.6, to publish, present or otherwise disclose any Confidential Information of the Reviewing other Party (including Sample Data), without such other Party’s prior written consent; provided that the Publishing Party Company shall have no obligation the right to delete any Study Data; and/or (ii) if such proposed publication publish, present or presentation contains patentable subject matter owned solely or jointly by otherwise disclose the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including Research Program Information with respect to results from such Party’s development activities outside any Acquired Compound or Acquired Product without the prior written consent of SpinCo, and SpinCo shall have the right to publish, present or otherwise disclose the Research Program Information with respect to any SpinCo Selected Compound or any Declined Compound without the prior written consent of the StudyCompany. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC. Notwithstanding the foregoing, (in accordance with this i) except for disclosures permitted pursuant to Section 8.2); provided that Corvus gives Genentech an opportunity 5.2, either Party, its employees or consultants wishing to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party make a publication shall submit deliver to the other Party (for purposes a copy of this Section, the “Reviewing Party”) all materials related to the proposed written publication or presentation (including posters, abstracts, manuscripts and written descriptions an outline of an oral presentations) disclosure at least [***] sixty (60) days (or [***]or, in the case of abstractsconsulting agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with such consultant) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing (ii) the reviewing Party shall review such submitted materials and respond have the right to the Publishing Party as soon as reasonably possible, but in any case within [***] require a delay of up to ninety (or [***]90) days (or, in the case of abstractsconsulting agreements, such shorter period (but not less than sixty (60) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request days) as required by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (iconsulting or other agreement with such consultant) delete from such proposed in publication or presentation Confidential Information of the Reviewing Party in order to enable patent applications protecting each Party’s rights in such information to be filed, and (including Sample Data), provided that the Publishing iii) each Party shall have no obligation the right to delete prohibit disclosure of any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay of its Confidential Information in any such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial In any permitted publication or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations presentation by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-ownership shall be determined in accordance with appropriate scientific customary standards. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (60) and academic standards ninety (90) day periods set forth in clauses (i) and customs(ii) above.

Publications and Presentations. (a) Corvus Sponsor may publish or present the final results of the Study Sponsor’s Study(ies) (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity , whether such results are positive or negative in any respect, such as with respect to review and provide comments the Combination or either Compound. Authorship of publications or presentations of any Study Data or Sample Data shall be determined in accordance with subsection (b). (b) appropriate scientific and academic standards and customs. In the event that either Party (for purposes of this SectionSection 8.2, the “Publishing Party”) wishes to publish or present any Study Data or Sample DataData (whether final or partial), the Publishing Party shall submit to the other Party (for purposes of this SectionSection 8.2, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], ] in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], ] in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request requests by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample DataData owned solely or jointly by the Reviewing Party), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for an additional [***], ] to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the StudyStudy(ies). 8.3 Press Releases and Other Public Disclosures. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. Amgen and Novartis shall be free to (a) Corvus may publish or provided that, with respect to Franchise Product 3, Novartis shall only have such rights after the Option Exercise Date): 11.6.1. present the final results of the Study (in accordance findings with this Section 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration respect to any request Licensed Product at symposia and other meetings of healthcare professionals, and international, national or regional congresses, conferences or meetings organized by the Reviewing Partya professional society or organization (any such occasion, a “Scientific Meeting”); provided, however, at unless otherwise agreed by the request of the Reviewing PartyParties, the Publishing Party shall that (i) delete from the Party presenting at any such proposed publication or presentation Confidential Information Scientific Meeting shall have complied with the provisions of the Reviewing Section 11.6 (Publications and Presentations) and Section 11.7 (Scientific Papers, Abstracts and Posters) with respect to such presentation, and, with respect to any such Scientific Meeting at which a Party (including Sample Data)is presenting, provided that the Publishing such presenting Party shall have no obligation inform the other Party of such Scientific Meeting and where invitation is required, invite the other Party to delete any Study Dataattend such Amgen Ref. No. 2015641252 Page 52 Scientific Meeting; and/or and (ii) if a Party shall not organize or sponsor any satellite symposia in a country outside its territory without the other Party’s prior written consent, not to be unreasonably withheld; 11.6.2. publish in medical and scientific journals and similar publications (“Medical Journals”) articles and papers, including primary reports of clinical data, secondary or pooled analyses, and review papers concerning any Licensed Product which have been prepared by or on behalf of such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay for publication outside or in the Territory and related to studies conducted after the Effective Date outside or in the Territory concerning such proposed publication or presentationLicensed Product (each a “Scientific Paper”); provided, for [***]however, that the Party proposing to permit the Reviewing Party to prepare and file a patent application. The Publishing Party publish such Scientific Paper shall comply have complied with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data 11.7 (Scientific Papers, Abstracts and do not apply to any other publications or presentations by a Party, including Posters) with respect to results from such Party’s development activities outside Scientific Paper; and 11.6.3. disclose any clinical data generated by such Party concerning any Licensed Product in clinical trial registries; provided, however, that the Party proposing to make such disclosure shall have provided the other Party at least [*] Business Days prior to such disclosure (to the extent practicable), a detailed description of the Studyproposed disclosure and shall have, in good faith, considered the comments made by the other Party. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that while scientific publications and presentations regarding results of Research, Development and Exploitation of Products by a Party is beneficial to both Parties, such scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance activities hereunder. Each Party agrees that, except as required by Applicable Law, it will not publish or present, or permit to be published or presented, the Confidential Information of the other Party, without the prior written approval of the other Party. Subject to the foregoing, each Party will provide the other Party with this Section 8.2); provided that Corvus gives Genentech an the opportunity to review and provide comments in accordance with subsection (b). (b) In each of the event that either Party (for purposes of this Section, the “Publishing submitting Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including information to be presented verbally) that relate to the subject Confidential Information at least [***] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***]] period, in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any unpatented technology disclosed in the case of abstracts) of receipt thereofsuch publication or presentation that it reasonably believes may be patentable. The Publishing publishing Party will be permitted to publish take into account the reasonable comments or present such Study Data or Sample Data, but shall give reasonable consideration to any request changes proposed by the Reviewing Party; providedother Party on any publication or presentation. Once such abstracts, howevermanuscripts or presentations have been reviewed and, at the request of the Reviewing where applicable, approved by each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party shall (i) delete from for review for a later submission for publication. Each Party also will have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall contribution will be duly recognized, and co-authorship will be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards. Notwithstanding the foregoing, during the Research Term, neither Party will publish nor present, nor permit to be published or presented, results of the Nonclinical Workplan, including the Product IP.

Publications and Presentations. (a) Corvus may publish or present the final results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***]” wishes to make a publication or public presentation related to this Agreement, “[***]” shall deliver to Intec Pharma a copy of the proposed written publication or an outline of the proposed oral presentation at least thirty (30) days (or, in the case of abstractsconsulting or Third Party research agreements, such shorter period as required by the consulting or other research agreement) prior to the date of submission for publication or presentation. Intec Pharma shall have the date right to delay such proposed publication or presentation for up to sixty (60) days (or, in the case of presentationconsulting or Third Party research agreements, whichever is earliersuch shorter period as required by the consulting or other research agreement) in order to file patent applications protecting Intec Pharma’s rights in any information included in such proposed publication or presentation to the extent such filings are consistent with Section 7.1.1 (Intec Pharma Prosecution Rights), and Intec Pharma shall have the right to request the removal or redaction of any of its Confidential Information in any such submitted materialsproposed publication or presentation. The Reviewing Party Intec Pharma shall review not make any publication or public presentation related to this Agreement or any activities hereunder, except for such submitted materials and respond publications or public presentations that (a) relate solely to the Publishing Party as soon as reasonably possible, but in any case within [***] general applicability of the Accordion Pill System and (b) do not directly or indirectly identify “[***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party”, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of Product, the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for Agreement “[***], to permit ”Technology or any specific activities conducted under the Reviewing Party to prepare and file a patent applicationResearch Plan. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (financial or otherwise) in connection with any publications and presentations“COMMISSION”). For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the StudySUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided activities hereunder. Except as required by Applicable Laws, each Party agrees that Corvus gives Genentech an it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of Asterisks denote such omission. 3/21/2019 <![CDATA[Collaborative Development & License Agreement]]> xxxxx://xxx.xxx.xxx/Archives/xxxxx/data/1177648/000119312512454422/d401292dex101.htm 47/136 1. Each Party shall provide to the JSC the opportunity to review and provide comments in accordance with subsection (b). (b) In any of the event that either Party (for purposes of this Section, the “Publishing submitting Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions or presentations (including information to be presented verbally) which relate to the Research Program, the Development of oral presentations) a Candidate or the Commercialization of a Product at least [*****] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [***]**] period, in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed by the Reviewing Party; provided, however, at the request of the Reviewing PartyJSC, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish or present the final The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication of results of the Study (research and Development activities hereunder. Accordingly, during the Research Term neither Party shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in accordance with such publications. For clarity, nothing in this Section 8.2); provided that Corvus gives Genentech an 13.5 shall limit Dynavax’s right to publish or present, during the Research Term, the results of any studies carried out by or on behalf of Dynavax prior to the Effective Date. Each Party agrees to provide the other Party the opportunity to review any proposed abstracts, manuscripts or presentations (including verbal presentations) that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Agreement at least [ * ] days prior to their intended submission for publication and provide comments agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time (resulting in accordance with subsection (b). (ba total of no more than [ * ] days from the provision of such abstracts, manuscripts or presentation by one Party to the other for review until [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. such Party’s submission of such abstracts, manuscripts or presentation for publication) In to secure patent protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to review and decide whether to delay the event that either publication and filing of patent applications under certain circumstances. Neither Party (for purposes of this Section, shall have the “Publishing Party”) wishes right to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing other Party (including Sample Data), provided that the Publishing Party shall have no obligation which is subject to delete Section 13.1. With respect to any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly made by the Reviewing Party, delay such proposed publication or presentation, for [***], AstraZeneca pursuant to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to publications or presentations Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Study Data or Sample Data and do not apply to any other publications or presentations by a PartyDynavax Technology in the Dynavax ISS, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study Collaboration ISS, CDs, Product and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customsCombination Product.

Publications and Presentations. (a) Corvus may BioNTech shall have the sole right, either itself or through its Affiliates or Sublicensees, to present or publish the results of, or present scientific information relating to, any activities under this Agreement PROVIDED THAT prior to the final results [***] the Parties will agree through the JSC on the content of any publications relating to the Study ([***] and/or [***]. Biotheus shall not make any publication or presentation relating to a Licensed Compound or Licensed Product without the prior written consent of BioNTech. If, in accordance with the requirements and limitations of this Section 8.210.3 (Publications and Presentations); provided that Corvus gives Genentech an opportunity , a Party desires to review and provide comments in accordance with subsection (b). (b) In publicly present or publish results or scientific information relating to a Licensed Compound or Licensed Product which publication contains the event that either Party (for purposes Confidential Information of this Sectionthe non-publishing Party, prior to doing so, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing publishing Party shall submit to the other will provide non-publishing Party (for purposes with drafts of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions or summaries of oral presentations) at least presentations that include such results or information. The non-publishing Party will respond no later than [***] days after receipt of such proposed publication or presentation or such shorter period as may be agreed to by the Parties. The publishing Party will delay any such proposed publication or presentation for a period up [***] days after the non-publishing Party receives such proposed publication or presentation to permit the non-publishing Party to make filings for patent protection and will otherwise remove its Confidential Information identified by the non-publishing Party in such publication or presentation. The Parties agree to acknowledge the contributions of one another in accordance with standard academic practice regarding authorship of scientific publication. Each Party agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party; provided that any listings or publications made pursuant to this Section 10.3 (Publications and Presentations). [***] will provide such assistance as [***] may reasonably require to obtain any consent or permission that may be required in order to publish data that originates from [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (activities hereunder or prepublication of patentable data and content. It is agreed that both Parties may issue press releases only pursuant to Section 7.2. As long as ImmunoGen has not exercised a Co-Development Option to a Licensed Product, Biotest shall be entitled to publish details, data and/or results on the Research Program or the Development Program, e.g., in accordance with scientific articles or oral presentations, pursuant to this Section 8.2); 7.3. Provided that ImmunoGen has exercised a Co-Development Option to a Licensed Product both Parties shall be entitled to publish in full range on the respective Licensed Product only pursuant to this Section 7.3. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program or the Development or Commercialization of a Licensed Product, including but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration under this Agreement, without the prior review by and the approval of, the JDC, with respect to Development activities or, provided that Corvus gives Genentech an ImmunoGen has exercised a Co-Development Option and a JMC has been established, the JMC, with respect to Commercialization activities. Each Party shall provide to the JDC the opportunity to review and provide comments in accordance with subsection (b). (b) In any of the event that either Party (for purposes of this Section, the “Publishing submitting Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions or presentations (including information to be presented verbally) which relate to the Research Program or the Development or Commercialization of oral presentations) a Licensed Product at least [***] days (or [***], in the case of abstracts) days prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of JDC within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([***]) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the case of JDC reasonably believes is patentable. Once such abstracts) of receipt thereof. The Publishing Party will be permitted to publish , manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed by the Reviewing Party; provided, however, at the request of the Reviewing PartyJDC, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the JDC for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing results of the Development Program without the prior review by and written approval of the other Party”) wishes to publish or present any Study Data or Sample Data, the Publishing . Each Party shall submit provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (for purposes of this Sectionincluding, the “Reviewing Party”without limitation, information to be presented verbally) all materials related that relate to the proposed Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Notwithstanding the foregoing, in the event that a Party reasonably requests a response by the other Party in less than * (including posters*) days, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards meetings and customs(b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Development Program in accordance with its internal publication guidelines.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Law, it will not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In be published or presented, the event that either results of the Development Program to the extent such results refer to or derive from the Xxxxxxxx IP, Millennium Technology IP or Other IP or otherwise constitute Confidential Information of the other Party (for purposes of this Section, the “Publishing PartyCovered Results”) wishes without the prior written approval of the other Party, which approval will not be unreasonably withheld, conditioned or delayed; provided, that it will not be deemed unreasonable for Millennium to withhold its consent to any request by Xxxxxxxx to publish or present any Study Data Covered Results relating to the Selected Molecules or Sample DataDesignated ARC Molecules. Subject to the foregoing, the Publishing each Party shall submit to will provide the other Party (for purposes with the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including information to be presented verbally) that relate to the Covered Results at least [***] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***]] period, in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any unpatented technology disclosed in the case of abstracts) of receipt thereofsuch publication or presentation that it reasonably believes may be patentable. The Publishing publishing Party will be permitted to publish take into account the reasonable comments or present such Study Data or Sample Data, but shall give reasonable consideration to any request changes proposed by the Reviewing Party; providedother Party on any publication or presentation. Once such abstracts, howevermanuscripts or presentations have been reviewed and, at the request of the Reviewing where applicable, approved by each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party shall (i) delete from for review for a later submission for publication. Each Party also will have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall contribution will be duly recognized, and co-authorship will be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Research Program or the Development Program without the prior review by the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Research Program or the Development Program at least * (*) days prior to its intended presentation or submission for publication, and provide comments such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in accordance with subsection (b). (b) such publication or presentation that it reasonably believes may be patentable. In the event that either Party the Parties disagree on a proposed publication or presentation, they will discuss the matter in good faith and the matter shall be decided in accordance with Section 2.1.5 as a Unanimous Decision, provided that if such Disputed Matter is not resolved by the Designated Senior Officers within * (for purposes *) days after the date the Designated Senior Officers first met to consider such Disputed Matter or * (*) days after the date the JEC first met to consider such Disputed Matter, whichever is later, then the Disputed Matter shall not be resolved in accordance with Section 13.1, but instead, ARQULE shall have the right to make the final decision on publication or presentation of this Sectionthe results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once such abstracts, manuscripts or presentations have been published or presented by each Party, the “Publishing Party”) wishes same abstracts, manuscripts or presentations do not have to publish or present any Study Data or Sample Data, the Publishing Party shall submit be provided again to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of review for a later submission for publication or publication. Each Party also shall have the date of presentation, whichever is earlier, of right to require that any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but its Confidential Information that is disclosed in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of be deleted prior to such publication or presentation; provided, that, ARQULE shall be permitted to use data generated by ARQULE and information about the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete Target in any Study Data; and/or (ii) if such proposed publication or presentation. In any permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards meetings. 12. Notwithstanding anything to the contrary in the Agreement, this Amendment or any Annual Research Plan, ARQULE shall perform the *studies for the DS Target * and customsDS shall bear all costs associated with such * studies, including, but not limited to, *, as requested by DS and agreed by ARQULE. A plan for the * studies for the DS Target *, including the costs, shall be agreed upon by the Parties. Any amendment, modification and/or update to such plan shall be discussed and agreed by the Parties. ARQULE shall invoice DS (a) quarterly in advance, at least * (*) days prior to each Calendar Quarter, for all ARQULE FTEs involved in performing or managing external performance of such * studies and (b) quarterly in arrears for all Third Party Costs associated with such * studies, including without limitation, * costs. DS shall pay such invoices for ARQULE FTEs at least * (*) days before the first day of each Calendar Quarter and shall pay such invoices for Third Party Costs within * (*) days after receipt thereof. 13. The Parties agree to issue a press release relating to this Amendment in the form attached hereto as Exhibit 1 within seven (7) days after the Effective Date. 14. In all other respects, the Agreement shall remain in full force and effect and shall not be modified hereby.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Research Program or the Development Program without the prior review by the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Research Program or the Development Program at least * (*) days prior to its intended presentation or submission for publication, and provide comments such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in accordance with subsection (b). (b) such publication or presentation that it reasonably believes may be patentable. In the event that either Party the Parties disagree on a proposed publication or presentation, they will discuss the matter in good faith and the matter shall be decided in accordance with Section 2.1.5 as a Unanimous Decision, provided that if such Disputed Matter is not resolved by the Designated Senior Officers within * (for purposes *) days after the date the Designated Senior Officers first met to consider such Disputed Matter or * (*) days after the date the JEC first met to consider such Disputed Matter, whichever is later, then the Disputed Matter shall not be resolved in accordance with Section 13.1, but instead, ARQULE shall have the right to make the final decision on publication or presentation of this Sectionthe results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once such abstracts, manuscripts or presentations have been published or presented by each Party, the “Publishing Party”) wishes same abstracts, manuscripts or presentations do not have to publish or present any Study Data or Sample Data, the Publishing Party shall submit be provided again to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of review for a later submission for publication or publication. Each Party also shall have the date of presentation, whichever is earlier, of right to require that any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but its Confidential Information that is disclosed in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of be deleted prior to such publication or presentation; provided, that, ARQULE shall be permitted to use data generated by ARQULE and information about the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete Target in any Study Data; and/or (ii) if such proposed publication or presentation. In any permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards meetings. 12. Notwithstanding anything to the contrary in the Agreement, this Amendment or any Annual Research Plan, ARQULE shall perform the *studies for the DS Target * and customsDS shall bear all costs associated with such * studies, including, but not limited to, *, as requested by DS and agreed by ARQULE. A plan for the * studies for the DS Target *, including the costs, shall be agreed upon by the Parties. Any amendment, modification and/or update to such plan shall be discussed and agreed by the Parties. ARQULE shall invoice DS (a) quarterly in advance, at least * (*) days prior to each Calendar Quarter, for all ARQULE FTEs involved in performing or managing external performance of such * studies and (b) quarterly in arrears for all Third Party Costs associated with such * studies, including without limitation, * costs. DS shall pay such invoices for ARQULE FTEs at least * (*) days before the first day of each Calendar Quarter and shall pay such invoices for Third Party Costs within * (*) days after receipt thereof. 13. The Parties agree to issue a press release relating to this Amendment in the form attached hereto as Exhibit 1 within seven (7) days after the Effective Date. 14. In all other respects, the Agreement shall remain in full force and effect and shall not be modified hereby. This Amendment may be executed as of the date first written above in any number of counterparts, each of which shall be an original, but all of which together shall constitute one and the same agreement. ArQule, Inc. By: /s/ Xxxxx Xxxxx Name: Xxxxx Xxxxx Title: Chief Executive Officer Daiichi Sankyo Co., Ltd. By: /s/Xxxxxxxx Xxxxxxxx Name: Xxxxxxxx Xxxxxxxx Title: Senior Executive Officer and Head of R&D Division * Contact: Toshiaki Sai Corporate Office, Corporate Communications Daiichi Sankyo Co., Ltd. (Japan) +00-0-0000-0000 Xxxxxxx X. Xxxx VP, Investor Relations/ Corp. Communications ArQule, Inc. (000) 000-0000 Woburn, MA, October 12, 2010 — ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology. “This technology has provided us with a unique and innovative approach for discovery in the treatment of cancer,” said Xx. Xxxxxxxx Xxxxxxxx, the Global Head of Research, Daiichi Sankyo. “We expect that the expansion of this collaboration will produce other drug candidates and lay the foundation for future growth in this field.” Consistent with the existing AKIP™ collaboration, the economic terms provided for in the expanded agreement include payments for research support, licensing fees for compounds discovered as a result of this research, milestone payments related to clinical development, regulatory review and sales, and tiered royalty payments on net sales of each product. Daiichi Sankyo will have an option to license compounds directed to the targets defined under the agreement following the completion of certain pre-clinical studies. ArQule retains the option to co-commercialize any resulting licensed products in the U.S. “Our initial drug discovery collaboration has identified a development candidate for one target, and we are optimizing advanced lead compounds for the other target,” said Xx. Xxxxxx X.X. Xxxx, chief scientific officer of ArQule. “The expansion of this collaboration will continue to deploy AKIP technology to discover novel kinase inhibitors for additional oncology targets over the next two years.” Kinases play pivotal roles in modulating diverse cellular activities and have been implicated as important mediators of certain forms of cancer and other diseases. The AKIP™ technology is based on a novel binding mode that leads to inhibition of target kinases by small molecules that do not compete with adenosine triphosphate (ATP). ArQule has identified binding sites in more than 200 kinases involved in multiple therapeutic areas that are amenable to such non-ATP competitive inhibition. ArQule’s ability to rationally design novel kinase inhibitors that encompass new chemical spaces allows for an expanding intellectual property estate. The Company believes that non-ATP competitive small molecule inhibitors may have fewer off-target side effects and utility in a broad range of human diseases. ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and upcoming Phase 3 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company’s pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Research Program or the Development or Commercialization of a Licensed Product to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Publishing PartyCovered Results”) wishes to publish or present any Study Data or Sample Data, without the Publishing prior review by and approval of the other Party. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***], in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or [***]presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Development, manufacture, use and Commercialization of a Licensed Product to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Lilly. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***]] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any unpatented Technology disclosed in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific customary industry standards. Notwithstanding the foregoing or anything to the contrary herein, ImmunoGen acknowledges and academic standards agrees that Lilly may publish the registration of the initiation of and customsresults of clinical trials that it conducts with respect to an Ab-May Product or Licensed Product on Lilly’s Clinical Trial Register to the extent required by Lilly policies and/or Applicable Laws and that such publication will not be a breach of the confidentiality obligations this Agreement.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC until such time as the JSC determines that the Publication Committee shall report to a different entity. Notwithstanding the foregoing, (in accordance with this i) except for disclosures permitted pursuant to Section 8.2); provided that Corvus gives Genentech an opportunity 5.2, either Party, its employees or consultants wishing to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party make a publication shall submit deliver to the other Party (for purposes a copy of this Section, the “Reviewing Party”) all materials related to the proposed written publication or presentation (including posters, abstracts, manuscripts and written descriptions an outline of an oral presentations) disclosure at least [***] sixty (60) days (or [***]or, in the case of abstractsconsulting agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with such consultant) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing (ii) the reviewing Party shall review such submitted materials and respond have the right to the Publishing Party as soon as reasonably possible, but in any case within [***] require a delay of up to ninety (or [***]90) days (or, in the case of abstractsconsulting agreements, such shorter period (but not less than sixty (60) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request days) as required by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (iconsulting or other agreement with such consultant) delete from such proposed in publication or presentation Confidential Information of the Reviewing Party in order to enable patent applications protecting each Party’s rights in such information to be filed, and (including Sample Data), provided that the Publishing iii) each Party shall have no obligation the right to delete prohibit disclosure of any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay of its Confidential Information in any such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial In any permitted publication or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations presentation by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-ownership shall be determined in accordance with appropriate scientific customary standards. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (60) and academic standards ninety (90) day periods set forth in clauses (i) and customs(ii) above.

Publications and Presentations. (a) Corvus Jazz may publish or present present, or permit to be published or presented, the final design or results of the Study Development, manufacture, use and Commercialization of the Licensed Product or Co-Development Product, if applicable (in accordance with this Section 8.2the “Covered Results”); provided that Corvus gives Genentech an opportunity . ImmunoGen agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing Party”) wishes Covered Results without the prior review by and approval of Jazz, which approval shall not be unreasonably withheld, conditioned or delayed; provided, that it shall be deemed reasonable for Jazz to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Jazz. Each Party shall submit provide to the other Party the opportunity to review each of the submitting Party’s proposed (a) abstracts and manuscripts for purposes of this Section, the “Reviewing Party”) all materials related scientific journals or conferences that relate to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of intended submission for publication or the date of presentationpublication, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond (b) presentations at scientific conferences (including information to be presented verbally) that relate to the Publishing Party as soon as reasonably possible, but in any case within Covered Results at least [***] (or [***], in the case of abstracts) of receipt thereofBusiness Days prior to its intended presentation. The Publishing Upon written request from a Party will be permitted to publish or present given within such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Partyapplicable review period, the Publishing other Party shall (i) delete from not submit such abstract or manuscript for publication or make such presentation until appropriate patent applications are filed to protect any unpatented Technology disclosed in such publication or presentation that such Party reasonably believes may be patentable and (ii) remove any Confidential Information of such Party that is disclosed in any such proposed publication or presentation Confidential Information of prior to such publication or presentation. Once such abstracts, manuscripts or presentations (or the Reviewing Party (including Sample Data)information contained therein) have been reviewed and, provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed applicable, modified for publication or presentation contains patentable subject matter owned solely pursuant to this Section 8.3, the same abstracts, manuscripts or jointly presentations (and the information contained therein) do not have to be provided again by one Party to the Reviewing Party, delay such proposed other Party for review for a later submission for publication. In any permitted publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations presentation by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (activities hereunder or prepublication of patentable data and content. It is agreed that both Parties may issue press releases only pursuant to Section 7.2. As long as ImmunoGen has not exercised a Co-Development Option to a Licensed Product, Biotest shall be entitled to publish details, data and/or results on the Research Program or the Development Program, e.g., in accordance with scientific articles or oral presentations, pursuant to this Section 8.2); 7.3. Provided that ImmunoGen has exercised a Co-Development Option to a Licensed Product both Parties shall be entitled to publish in full range on the respective Licensed Product only pursuant to this Section 7.3. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program or the Development or Commercialization of a Licensed Product, including but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration under this Agreement, without the prior review by and the approval of, the JDC, with respect to Development activities or, provided that Corvus gives Genentech an ImmunoGen has exercised a Co-Development Option and a JMC has been established, the JMC, with respect to Commercialization activities. Each Party shall provide to the JDC the opportunity to review and provide comments in accordance with subsection (b). (b) In any of the event that either Party (for purposes of this Section, the “Publishing submitting Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions or presentations (including information to be presented verbally) which relate to the Research Program or the Development or Commercialization of oral presentations) a Licensed Product at least [***] days (or [***], in the case of abstracts) days prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of JDC within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([***]) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the case of JDC reasonably believes is patentable. Once such abstracts) of receipt thereof. The Publishing Party will be permitted to publish , manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed by the Reviewing Party; provided, however, at the request of the Reviewing PartyJDC, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the JDC for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific customary industry standards. Portions of this Exhibit were omitted and academic standards and customshave been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Research Program to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Lilly. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***]] from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with this Section 8.2); provided that Corvus gives Genentech an 2.1. Each Party shall provide to the JSC the opportunity to review and provide comments in accordance with subsection (b). (b) In any of the event that either Party (for purposes of this Section, the “Publishing submitting Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions or presentations (including information to be presented verbally) which relate to the Research Program, the Development of oral presentations) a Candidate or the Commercialization of a Product at least [*****] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [***]**] period, in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed by the Reviewing Party; provided, however, at the request of the Reviewing PartyJSC, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish or present the final The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication of results of the Study (research and Development activities hereunder. Accordingly, during the Research Term neither Party shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in accordance with such publications. For clarity, nothing in this Section 8.2); provided that Corvus gives Genentech an 13.5 shall limit Dynavax’s right to publish or present, during the Research Term, the results of any studies carried out by or on behalf of Dynavax prior to the Effective Date. Each Party agrees to provide the other Party the opportunity to review any proposed abstracts, manuscripts or presentations (including verbal presentations) that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Agreement at least [ * ] days prior to their intended submission for publication and provide comments agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time (resulting in accordance with subsection (b). (ba total of no more than [ * ] days from the provision of such abstracts, manuscripts or presentation by one Party to the other for review until such Party’s submission of such abstracts, manuscripts or presentation for publication) In to secure patent protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to review and decide whether to delay the event that either publication and filing of patent applications under certain circumstances. Neither Party (for purposes of this Section, shall have the “Publishing Party”) wishes right to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing other Party (including Sample Data), provided that the Publishing Party shall have no obligation which is subject to delete Section 13.1. With respect to any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly made by the Reviewing Party, delay such proposed publication or presentation, for [***], AstraZeneca pursuant to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to publications or presentations Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Study Data or Sample Data and do not apply to any other publications or presentations by a PartyDynavax Technology in the Dynavax ISS, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study Collaboration ISS, CDs, Product and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customsCombination Product.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study activities hereunder. Notwithstanding anything to the contrary contained herein, the right to publish or present, or permit to be published or presented, the results of the Research Program shall be governed by the terms of the Collaborative Research Agreement. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. In the event that the Parties disagree on a proposed publication or presentation, they will discuss the matter in good faith and ARQULE shall have the right to make the final decision on publication or presentation of the results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once such abstracts, manuscripts or presentations have been published or presented by each Party in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section5.3, the “Publishing Party”) wishes same abstracts, manuscripts or presentations do not have to publish or present any Study Data or Sample Data, the Publishing Party shall submit be provided again to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of review for a later submission for publication or publication. Each Party also shall have the date of presentation, whichever is earlier, of right to require that any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but its Confidential Information that is disclosed in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], provided that ARQULE shall be permitted to permit the Reviewing Party to prepare use data generated by ARQULE and file a patent applicationinformation about AKT in any such publication or presentation. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial In any permitted publication or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations presentation by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards and customsmeetings.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Research Program to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Lilly. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***]] days [***] from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing results of the Research Program or the Development Program without the prior review by and written approval of the other Party”) wishes to publish or present any Study Data or Sample Data, the Publishing . Each Party shall submit provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (for purposes of this Sectionincluding, the “Reviewing Party”without limitation, information to be presented verbally) all materials related that relate to the proposed Research Program or the Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation (including posters, that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate customary standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and academic standards meetings and customs(b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the research conducted by sanofi-aventis under or pursuant to this Agreement to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Publishing PartyCovered Results”) wishes to publish or present any Study Data or Sample Data, without the Publishing prior review by and approval of the other Party. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the date of submission other Party given within such [***]-[***] period, not to submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]) days from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. Each of Amgen and KKC shall be free to: 12.6.1 present findings with respect to the Product at symposia and other meetings of healthcare professionals, and congresses, conferences or meetings organized by a professional society or organization (aany such occasion, a “Scientific Meeting”); provided, however, unless otherwise agreed by the Parties, that (i) Corvus may publish or present the final results Party presenting at any such Scientific Meeting shall have complied with the provisions of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity 12.6 and Section 12.7 (Scientific Papers, Abstracts and Posters) with respect to review and provide comments in accordance such presentation, and, with subsection (b). (b) In the event that either respect to any such Scientific Meeting at which a Party (for purposes of this Sectionis presenting, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing such presenting Party shall submit to inform the other Party of such Scientific Meeting and where invitation is required, invite the other Party to attend such Scientific Meeting; and (ii) a Party shall not organize or sponsor any satellite symposia in a country outside its territory without the other Party’s prior written consent, not to be unreasonably withheld; 12.6.2 publish in medical or scientific journals (“Medical Journals”) articles and papers, including primary reports of clinical data, data obtained from Investigator Sponsored Studies, secondary or pooled analyses, and review papers concerning the Product which have been prepared by or on behalf of such Party, for purposes publication in the Amgen Territory or in the KKC Territory and related to studies conducted after the Effective Date outside or in the Territory concerning the Product (each a “Scientific Paper”); provided, however, that the Party proposing to publish such Scientific Paper shall have complied with the provisions of this SectionSection 12.7 (Scientific Papers, Abstracts and Posters) with respect to such Scientific Paper; and 12.6.3 disclose any clinical data generated by such Party concerning the Product in clinical trial registries; provided, however, that, the “Reviewing Party”) all materials related Party proposing to make such disclosure shall have provided the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) other Party at least [***] days Business Days prior to such disclosure (or [***]to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request comments made by the Reviewing other Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Development, manufacture, use and Commercialization of a Licensed Product to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Lilly. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***], in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any unpatented Technology disclosed in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific customary industry standards. Notwithstanding the foregoing or anything to the contrary herein, ImmunoGen acknowledges and academic standards agrees that Lilly may publish the registration of the initiation of and customsresults of clinical trials that it conducts with respect to an Ab-May Product or Licensed Product on Lilly’s Clinical Trial Register to the extent required by Lilly policies and/or Applicable Laws and that such publication will not be a breach of the confidentiality obligations this Agreement.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Research Program to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Novartis to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the publication or Sample Data, the Publishing dissemination of such Covered Results by Novartis. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***], in the case of abstracts) prior not to the date of submission submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or [***]presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided activities hereunder. Except as required by Applicable Laws, each Party agrees that Corvus gives Genentech an opportunity it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the “Publishing results of the Development Program or the Development or Commercialization of a Collaboration Product or Collaboration Service, including but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration under this Agreement, without the prior review by and the approval of the other Party”) wishes to publish or present any Study Data or Sample Data, the Publishing . Each Party shall submit provide to the other Party the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (for purposes of this Section, the “Reviewing Party”including information to be presented verbally) all materials related which relate to the proposed Development Program or the Development or the Commercialization of a Collaboration Product or Collaboration Service at least thirty (30) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party within such thirty (30) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to sixty (60) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation (including posters, which the other Party reasonably believes is patentable. Once such abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed by the Reviewing Party; provided, however, at the request of the Reviewing other Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again, to the either Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus may Kite is committed to timely publication of the final results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study. Kite shall have the right to first publish or present any interim results and the final results of the Study (in accordance with this Section 8.2); provided that Corvus Kite gives Genentech Humanigen an opportunity to review and provide comments in accordance with subsection (b), with such comments to be included at Kite’s sole discretion. Humanigen agrees not to publish any results of the Study or Sample Data (including any interim Study results or Sample Data) prior to the timely publication of such Study results by Kite. (b) In the event that either Each Party (for purposes of this Section, the “Publishing Party”) wishes shall use reasonable efforts to publish or present scientific papers dealing with the Study in accordance with accepted scientific practice. The Parties agree that prior to submission of the Study results for publication or presentation or any Study Data or Sample Dataother dissemination of results, including oral presentations, the Publishing publishing Party shall submit invite the other to comment on the content of the material to be published or presented according to the following procedure: (i) At least forty-five (45) days prior to submission for publication of any paper, letter or any other publication, or thirty (30) days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party (for purposes the full details of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation in an electronic version. Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional ninety (including posters, abstracts, manuscripts and written descriptions of oral presentations90) at least [***] days in order to allow for actions to be taken to preserve rights for patent protection. (or [***], in the case of abstractsii) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing publishing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at other Party made within the request of the Reviewing Party, the Publishing Party shall periods set forth in subsection (i) delete from such proposed above to modify the publication or presentation and the Parties shall work in good faith and in a timely manner to resolve any issue regarding the content for publication. (iii) The publishing Party shall remove all Confidential Information of the Reviewing other Party (including Sample Data), provided that as requested by such other Party before finalizing the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Studypublication. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Development or Commercialization of a Licensed Product to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Publishing PartyCovered Results”) wishes to publish or present any Study Data or Sample Data, without the Publishing prior review by and approval of the other Party. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the date of submission other Party given within such [***]-[***] period, not to submit such abstract or manuscript for publication or to make such presentation until the date of presentation, whichever other Party is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond given up to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***]) days from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete such publication or presentation. In any Study Data; and/or (ii) if such proposed permitted publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such the other Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data contribution shall be duly recognized, and co-authorship shall be determined in accordance with appropriate scientific and academic standards and customscustomary industry standards.

Publications and Presentations. (a) Corvus Genentech may publish or present the final results of the Study (in accordance with this Section 8.2), whether such results are positive or negative in any respect, such as with respect to the Combination or either Compound; provided that Genentech gives Corvus gives Genentech an opportunity to review and provide comments comments. Authorship of publications or presentations of any Study Data or Sample Data shall be determined in accordance with subsection (b). (b) appropriate scientific and academic standards and customs. In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [***] days (or [***], in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (or [***], in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample DataData owned solely or jointly by the Reviewing Party), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.to

Publications and Presentations. (a) Corvus may publish The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or present the final dissemination of results of the Study (in accordance with this Section 8.2); provided that Corvus gives Genentech an opportunity activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Sectionbe published or presented, the results of the Development, manufacture, use and Commercialization of a Licensed Product to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Publishing PartyCovered Results”) wishes without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Study Data Covered Results prior to the planned publication or Sample Data, the Publishing dissemination of such Covered Results by Lilly. Each Party shall submit provide to the other Party (for purposes the opportunity to review each of this Section, the “Reviewing submitting Party”) all materials related to the ’s proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentationsor presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days (or [***], in the case of abstracts) prior to the date of its intended presentation or submission for publication or publication, and such submitting Party agrees, upon written request from the date of presentation, whichever is earlier, of any of other Party given within such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [***] (day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***]] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any unpatented Technology disclosed in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish manuscripts or present such Study Data or Sample Data, but shall give reasonable consideration to any request presentations have been reviewed and approved by the Reviewing Party; provided, however, at the request of the Reviewing each Party, the Publishing same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall (i) delete from have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation be deleted prior to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with In any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs.permitted publication or